Mobile Menu

Pharma-published AI & RWD articles

Benjamin Hughes, Senior Vice President of AI and RWD at IQVIA, has collated the sixteen most interesting publications from this month that are within his remit, and we thought it’s a great resource to share.

Janssen Pool IBM® MarketScan®, Optum ClinformaticsTM, and IQVIA PharMetrics PlusTM to profile resource utilisation of Crohn’s Disease Treated with Ustekinumab

Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn’s Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States Obando C, Ding Z, Muser E, Vaidya N, Qiang W, Sun X, Wang H, Mallampati R, Xie L.

Sanofi – Lever the REACHnet network (PCORI) to examine simultaneous initiation of basal insulin and glucagon-like peptide-1 receptor agonists impact on HbA1c

Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study. Peng XV, Ayyagari R, Lubwama R, Shi L, Price-Haywood E, Hollander P, Fonseca V.

GSK – Lever IBM Marketscan/Medicaid to profile the opportunity for improved vaccination rates in adult population

The adult vaccination landscape in the United States during the Affordable Care Act era: Results from a large retrospective database analysis. Aris E, Montourcy M, Esterberg E, Kurosky SK, Poston S, Hogea C.

Amgen – Via chart reviews with Kantar profile bone complications across 800 patients with multiple myeloma in five European countries

Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review María-Victoria Mateos, Leah Fink, Niranchana Koneswaran, Michele Intorcia, Christina Giannopoulou, Daniela Niepel & Michele Cavo

Astellas – Lever Japan MDV to profile hospital stay, mortality and cost attributable to Clostridioides (Clostridium) difficile infection and recurrence

Excess length of hospital stay, mortality and cost attributable to Clostridioides (Clostridium) difficile infection and recurrence: a nationwide analysis in Japan. Kimura T, Stanhope S, Sugitani T.

Novartis – Lever IQVIA EMR Germany to profile corticosteroid co-morbidities

Systemic corticosteroid use in relation to development of corticosteroid-associated co-morbidities: a 2 year analysis of real world data in Germany Lommatzsch M, Wilmer C, Schwab Sauerbeck I.

CDCC – Lever data from National Infectious Disease Monitoring Information System (NIDMIS) by the Guangdong CDC to profile changes in measles rate

Epidemiological changes in measles infections in southern China between 2009 and 2016: a retrospective database analysis Huizhen Zheng, Katherine Min Jia, Riyang Sun, Pui Hu, Maggie Haitian Wang, Benny Chung-Ying Zee, Wenjia Liang & Ka Chun Chong

Pfizer – Lever OPAL (Optimising Patient outcomes in Australian Rheumatology) DB to show Tofacitinib treatment effectiveness and persistence similar to bDMARD

Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia. Bird P, Littlejohn G, Butcher B, Smith T, da Fonseca Pereira C, Witcombe D, Griffiths H

Eli Lilly – Lever IBM Marketscan on 2000 patients to suggest adherence and persistence for HR U-500 insulin is comparable as a mono-therapy (better than prior publications)

Treatment Patterns, Adherence, and Persistence Associated With Human Regular U-500 Insulin: A Real-World Evidence Study. J Chen, CY Kao, X He, L Fan, JA Jackson, R Juneja

Osaka – Levers FDA FAERS data and Japan JMDC to suggest there is no association between antipsychotic use and the onset of osteoporosis

Association Between Antipsychotics and Osteoporosis Based on Real-World Data. Yokoyama S, Wakamoto S, Tanaka Y, Nakagawa C, Hosomi K, Takada M

AstraZeneca – Levers SEER-Medicare data to profile survival with chemoradiation versus single modality therapy in stage III non-small cell lung cancer

Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer P Bobbili, K Ryan, M DerSarkissian, A Dua, C Yee, MS Duh, JE Gomez, JSH Heieh

Janssen – On the use of genomics in R&D (discovery to phase III) in CKD, including describing basic concepts in genomics and analyses performed at each development stage

The Use of Genomics to Drive Kidney Disease Drug Discovery and Development. DF Reilly, MD Breyer

Novartis – Lever Finish registry data to examine clinical diagnostics of heart failure patients with reduced or preserved ejection fraction

Real-world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction. Huusko J, Purmonen T, Toppila I, Lassenius M, Ukkonen H

Pharnext – Call for RWE to evaluate drugs for repositioning for COVID, profiling 97 potential candidates via initial analysis of literature and use of four druggable protein pathways

Focusing on the Unfolded Protein Response and Autophagy Related Pathways to Reposition Common Approved Drugs against COVID-19. S Nabirotchkin, AE. Peluffo, Jan Bouaziz, D Cohen

Pfizer – Lever AOK PLUS Germany sick fund database to profile the burden of Staphylococcus aureus infections after orthopaedic surgery in Germany

Burden of Staphylococcus aureus infections after orthopedic surgery in Germany F Hardtstock, K Heinrich, T Wilke, S Mueller & H Yu

More on these topics

AI / Real World Data / Research

Share this article